274.76
-0.97(-0.35%)
Currency In USD
| Previous Close | 275.73 |
| Open | 279.48 |
| Day High | 279.48 |
| Day Low | 270.01 |
| 52-Week High | 286.5 |
| 52-Week Low | 26.7 |
| Volume | 208,943 |
| Average Volume | 1.05M |
| Market Cap | 5.81B |
| PE | -21.17 |
| EPS | -12.98 |
| Moving Average 50 Days | 199.96 |
| Moving Average 200 Days | 82.55 |
| Change | -0.97 |
If you invested $1000 in Praxis Precision Medicines, Inc. (PRAX) since IPO date, it would be worth $658.9 as of December 25, 2025 at a share price of $274.76. Whereas If you bought $1000 worth of Praxis Precision Medicines, Inc. (PRAX) shares 3 years ago, it would be worth $8,033.92 as of December 25, 2025 at a share price of $274.76.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026
GlobeNewswire Inc.
Dec 11, 2025 1:00 PM GMT
EMBOLD data to serve as basis of efficacy and safety following discussion with the FDABOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights
Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy
GlobeNewswire Inc.
Dec 09, 2025 9:01 PM GMT
Clear recognition of high unmet need and urgency for the SCN2A community and plausibility of the mechanism of elsunersen FDA agreed to proposed changes to the EMBRAVE3 trial design to be a single-arm, baseline-controlled study Enrollment in EMBRAVE3
Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies
GlobeNewswire Inc.
Dec 08, 2025 1:00 PM GMT
Positive Results in the EMBOLD study of relutrigine showed a 53% placebo-adjusted reduction in seizures (p < 0.0002), 66% increase in motor seizure-free days (p = 0.0340), broad and clinically meaningful functional improvements (p ≤ 0.002) Patients i